This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While advanced analytics and AI can unlock unprecedented insights, it’s the thoughtful application of these insights that transforms routine interactions between pharmaceutical representatives and healthcareproviders into lasting relationships.
We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcareproviders, and personalized medicine practices such as pharmacogenomics.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcareproviders and payers. appeared first on MedCity News.
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcareproviders to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.
However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcareproviders (HCPs) as consumers. The post Access solutions: the missing link that prevents biopharma innovation from reaching patients appeared first on.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence.
Bryan Johnson Senior Director, Product Management, Compass Prescriber Veeva Systems Paving the Way to Faster Treatment Starts Bryan’s exposure to life sciences started at a young age, watching his father’s career at companies like Johnson & Johnson and emerging biopharmas. As rare diseases affect about 1 in 10 people in the U.S.,
“Streaming video provides life sciences advertisers with an efficient and effective way to reach patients at any stage of treatment and can help advance their patient marketing efforts.” Biopharma marketers are following their audiences and investment in this channel continues to increase.
Powered by the company’s customer relationship management system, the CGT integration hub is a platform-agnostic system that aims to improve connectivity across the CGT treatment journey, enhancing the experience for patients and healthcareproviders.
Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017).
Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).
Ittai Dayan , Co-founder & CEO of Rhino Health , will join Natalie Yeadon , Co-founder & CEO of Impetus Digital , to share how his company is transforming the way healthcare AI solutions are created, adopted and measured. Register now! Register for this free webinar. Book a Consultative Demo.
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.
Aimed at patients, caregivers, and healthcareproviders, the tool is a key component of NovoCare’s comprehensive approach to disease education and simplifies the intricate insurance verification process. FINALISTS: Crack the JAK (Scientific Global) Don’t Sweat Inventory Management (Accord Biopharma, Inc. &
AZ’s head of biopharma R&D Mene Pangalos said the new device would help support the use of Tezspire to treat “a broad population of severe asthma patients.” ” It is estimated that there are 2.5 million patients worldwide with severe asthma who are uncontrolled, without any phenotypic and biomarker limitation.
Though 80% of healthcareproviders (HCPs) identified as “rep-accessible” in 2008 (that is, willing to meet with over 70% of the sales reps who try to approach them), that number had decreased to 44% in 2017. No biopharma or device advertisements appear during the prescribing workflow.
Get continuous, automatic data updates to improve sales rep productivity and drive intelligent engagement with healthcareproviders. Have visibility into relationships between healthcareproviders and organisations to improve targeting, eliminate territory coverage gaps, and create account-based selling plans.
Through this collaboration, healthcareproviders are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.
Collaboration across the entire ecosystem—from policymakers and regulators to healthcareproviders to researchers—is critical for creating an environment where innovation can thrive. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. With this in mind, our efforts to reach these people should focus on providing answers, information, and hope—with all the necessary caveats. Many people, cumulatively, are affected.
Ittai Dayan , Co-founder & CEO of Rhino Health , shared how his company is transforming the way healthcare AI solutions are created, adopted and measured. Book a Consultative Demo The post Diversifying Healthcare AI with Federated Learning appeared first on Impetus Digital.
In the pharmaceutical sector, this evolved further with privacycompliant data enrichment, enabling hyper-personalized messaging for healthcareproviders (HCPs). By tracking preferences and behaviors, companies tailored interactions to make them more meaningful and effective.
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcareproviders and patients through product support, education, and training. Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses.
DANNY SIGURDSON CEO and Founder Courier Health To effectively engage patients and prescribers to improve overall adherence to prescribed medication regimens, biopharma companies first need the visibility and full context of where a patient stands in their treatment journey. Support healthcareproviders in a real and personal way.
In recent years, we’ve seen an increase in awareness among healthcareproviders and better diagnosis of rare diseases, leading to improved access to care for patients with these uncommon conditions. Learn more about the Clarivate real world data offering here.
These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcareprovider.
Manufacturers, healthcareproviders, and consumers alike face the need to quickly adapt. A chance to innovate: Global health impacts our world and there are various stakeholders making choices, from manufacturers to healthcareproviders and patients. Impending change affords an opportunity for innovation.
“HealthCentral has a long history of providing thoroughly researched, engaging content that informs and empowers people with serious illness to live well and thrive,” stated Steve Zatz, MD, Chairman and Chief Executive Officer of HealthCentral Corp.
Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcareproviders, and happier and healthier people around the world.” Weiss has also made substantial efforts to give back to the community at large.
The existence of biosimilars is meant to address both the cost and access of biologics in the healthcare industry. [1] The global biosimilars market is projected to grow beyond $68 billion by 2028, as more biologic patents are set to expire and generic manufacturers are expected to enter and evolve the market with their business practices. [4]
Furthermore, entire value chains must be redesigned and the CO 2 emitters (especially point source emitters), chemical industry and power sector, downstream users, eg, healthcare industries and their customers, and healthcareproviders need to be coordinated, informed, sensitised and must work out contractual frameworks to de-risk the investments.
These computational tools offer novel insights to enable drugging of biological targets that have been undruggable to date and hold immense potential to give scientists, healthcareproviders, and patients the tools to address a variety of cancer types in the most comprehensive way possible.
healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. In a fiercely competitive U.S.
Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. In addition, Medical Affairs personnel are an important resource for healthcareproviders and typically focus on the disease and data from the relevant clinical trials.
The current legal landscape makes access to medication abortion crucial in protecting as much access to reproductive healthcare as possible and in protecting healthcareproviders’ abilities to do their jobs without fear of prosecution.
For example, a biopharma may want to track the improvement in patient adherence to a therapy pre- and post-launch of a PSP across regions to gauge its impact. Additionally, ensuring healthcareproviders are aware of and can easily enroll patients in manufacturer cost-saving programs may be vital to patient affordability of treatment.
The future of healthcare will be one where technology doesn’t just serve the industry but genuinely improves the lives of individuals, transforming how we interact with medical data, healthcareproviders, and our personal well-being.
We are poised to accelerate groundbreaking RNA therapy and vaccines for biopharma customers while becoming the reference lab for the cell and gene therapies of tomorrow. A lot of unique assays have already been added to a common portfolio and colleagues from both businesses are working well together.
Mario Papillon, CEO of Cerba Research comments: “ This MoU is an important milestone with Teddy Lab which demonstrates our commitment to expand our footprint into new geographic territories and to best support our global biopharma customers in their evolving needs.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content